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 INTRODUCTION 
 
              Over the last decade, cardiovascular disease (CVD) has become the 
single largest cause of death worldwide.1They account for about 30% of all 
cause of death.2 IHD is the most common, serious, chronic, life-threatening 
illness in the world.2 
 
              Traditional risk factors include modifiable and non-modifiable risk 
factors. Non modifiable risk factors include age, sex, race, family history, 
personal history. Modifiable risk factors include cigarette smoking, obesity, 
Physical inactivity, Kidney disease, Diabetes mellitus, Alcohol consumption, 
Stress, elevated LDL, and reduced HDL.1, 3  
 
             In recent years, new serum markers have been used in the diagnosis and 
risk stratification of patients with acute ischemic heart disease. These markers 
of myocardial damage are systematically employed in the diagnosis and 
prognosis of acute coronary syndromes.4 It has been suggested that 
inflammation influences the pathogenesis of atherosclerosis and the progression 
of acute coronary syndromes.5  
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Consequently, markers of inflammation are also used in prognostic 
stratification of acute coronary syndromes.6 Among these markers, C-reactive 
protein (CRP) is preferred because of its availability, stability, and prolonged 
average life.7  
 
          In this background a cross sectional study was done in 52 patients 
admitted with features of acute coronary syndrome. Hs-CRP was measured and 
level was compared to the angiographic severity of the lesion 
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REVIEW OF LITERATURE 
Definition: 
Patients with ischemic heart disease fall into two large groups:  
              Patients with chronic coronary artery disease (CAD) who most 
commonly present with stable angina and patients with acute coronary 
syndromes (ACSs). The latter group, in turn, is composed of patients with acute 
myocardial infarction (MI) with ST-segment elevation on their presenting 
electrocardiogram (ECG) (STEMI) and those with unstable angina (UA) and  
non-ST-segment elevation MI. 
Acute Coronary Syndrome: 
Revised Definition of Myocardial Infarction8 
Criteria for Acute, Evolving, or Recent MI: 
Either of the following criteria satisfies the diagnosis for acute, evolving, or 
recent MI: 
1 Typical rise and/or fall of biochemical markers of myocardial necrosis with at 
least one of the following:   
   a.     Ischemic symptoms 
   b.     Development of pathologic Q waves in the ECG 
3
     c.     E lectrocardiographic changes indicative of ischemia (ST-segment 
elevation or depression) 
    d.     Imaging evidence of new loss of viable myocardium or new  
regional wall motion abnormality 
    2     Pathologic findings of an acute myocardial infarction 
 Criteria for Healing or Healed Myocardial Infarction:  
Any one of the following criteria satisfies the diagnosis for healing or 
healed myocardial infarction: 
   1     D evelopment of new pathologic Q waves in serial ECGs. The patient  
may or may not remember previous symptoms. Biochemical markers of 
myocardial necrosis may have normalized, depending on the length of time that 
has passed since the infarction developed. 
  2      Pathologic findings of a healed or healing infarction                         
 Classification of Myocardial Infarction: 
TYPE    FEATURES  
 1        Spontaneous myocardial infarction related to ischemia caused by a  
primary coronary event   s uch as plaque erosion and/or rupture, fissuring, or 
dissection  
  2.       Myocardial infarction secondary to ischemia caused by increased  
4
  oxygen demand or decreased supply (e.g., coronary artery spasm,  
 coronary embolism, anemia, arrhythmias, hypertension, hypotension)  
3.       Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischemia, accompanied by  presumably 
new ST-segment elevation, or new  L BBB, or presumably new major 
obstruction in a coronary artery by angiography and/or pathology, but death 
occurring before blood samples could be obtained, or before the  appearance of 
cardiac biomarkers in the blood  
4a       Myocardial infarction associated with PCI  
4b  Myocardial infarction associated with stent thrombosis, as documented by 
angiography or autopsy  
5         Myocardial infarction associated with CABG 
Unstable angina and NSTEMI: 
UA is defined as angina pectoris or equivalent ischemic discomfort with 
at least one of three features:  
(1) It occurs at rest (or with minimal exertion), usually lasting >10  
 minutes;  
           (2) It is severe and of new onset (i.e., within the prior 4–6 weeks); and/or  
          (3) It occurs with a crescendo pattern (i.e., distinctly more severe,  
5
prolonged, or frequent than previously).  
The diagnosis of NSTEMI is established if a patient with the clinical 
features of UA develops evidence of myocardial necrosis, as reflected in 
elevated cardiac biomarkers.1, 2 
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Risk factors: 
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Traditional risk factors: 
Smoking: 
           Other than advanced age, smoking is the single most important risk 
factor for coronary artery disease. Cigarette consumption is the leading 
preventable cause of death in the United States, where it accounts for more than 
400,000 deaths annually.9 Ischemic heart disease causes 35% to 40% of all 
smoking-related deaths, with an additional 8% attributable to second-hand 
smoke exposure. 
             Cessation of cigarette consumption overwhelmingly remains the single 
most important intervention in preventive cardiology. In a major overview, 
smoking cessation was found to reduce CHD mortality by 36% as compared 
with mortality in subjects who continued smoking, an effect that did not vary by 
age, sex, or country of origin.10  
Lipid disorders: 
           The Framingham Heart Study results demonstrated that the higher the 
cholesterol level, the greater the risk of coronary artery disease (CAD); 
alternatively, CAD was uncommon in people with cholesterol levels below 150 
mg/dL. In 1984, the Lipid Research Clinics-Coronary Primary Prevention Trial 
revealed that lowering total and LDL or bad cholesterol levels significantly 
reduced CAD. More recent series of clinical trials using statin drugs have 
provided conclusive evidence that lowering LDL cholesterol reduces the rate of 
8
myocardial infarction (MI), the need for percutaneous coronary intervention and 
the mortality associated with CAD-related causes.11 
Hypertension: 
           Hypertension currently is defined as a usual BP of 140/90 mm Hg or 
higher, for which the benefits of drug treatment have been definitively 
established in randomized placebo-controlled trials.12 High blood pressure often 
confers silent cardiovascular risk, and its prevalence is steadily increasing. 
          Hypertension, along with other factors such as obesity, have been said to 
contribute to the development of left ventricular hypertrophy (LVH). LVH has 
been found to be an independent risk factor to cardiovascular disease morbidity 
and mortality. It roughly doubles the risk of cardiovascular death in both men 
and women.15 
Diabetes mellitus: 
           Insulin resistance and diabetes rank among the major cardiovascular risk 
factors; in one major survey, the presence of diabetes conferred an equivalent 
risk to aging 15 years, an impact higher than that of smoking.13 
          Obesity is associated with elevated vascular risk in population studies. In 
addition, this condition has been associated with glucose intolerance, insulin 
resistance, hypertension, physical inactivity, and dyslipidemia.14 
Lack of activity: 
9
          The cardio protective benefits of exercise include reducing adipose tissue, 
which decreases obesity; lowering blood pressure, lipids, and vascular 
inflammation; improving endothelial dysfunction, improving insulin sensitivity, 
and improving endogenous fibrinolysis.16 
          Studies have also shown that even 15 minutes a day or 90 minutes a week 
of moderate-intensity exercise may be beneficial.17 
Mental stress, depression, cardiovascular risk: 
          Depression has been strongly implicated in predicting CAD.18.  
Adrenergic stimulation during stress can increase myocardial oxygen 
requirements, can cause vasoconstriction, and has been linked to platelet and 
endothelial dysfunction19 and metabolic syndrome.20 
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Non Traditional Risk Factors: 
hs-CRP: 
         Inflammation characterizes all phases of atherothrombosis and provides a 
critical pathophysiologic link between plaque formation and acute rupture, 
which lead to occlusion and infarction.21 The acute-phase reactant CRP, a 
simple downstream marker of inflammation, has now emerged as a major 
cardiovascular risk marker.22 
Lipoprotein A:(LpA) 
        An elevated lipoprotein(a) [Lp(a)] level is an independent risk factor of 
premature CAD23 and is  particularly a significant risk factor for premature 
atherothrombosis and cardiovascular events. Measurement of Lp(a) is more 
useful for young individuals with a personal or family history of premature 
vascular disease and  repeat coronary interventions. 
Homocysteine: 
        Homocysteine is a sulfhydryl-containing amino acid derived from the 
demethylation of dietary methionine. Patients with rare inherited defects of 
methionine metabolism can develop severe hyperhomocysteinemia (plasma 
levels higher than 100 mmol/liter) and have a markedly elevated risk of 
premature atherothrombosis and venous thromboembolism.1  In the general 
population, mild to moderate elevations are due to insufficient dietary intake of 
folic acid and folate antagonists.1 
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Other risk factors include ESRD, inflammatory markers like 
myeloperoxidase, IL-6, P-selectin, ICAM etc. are also potential risk factors for 
CAD. 
Future Directions in Cardiovascular Risk Assessment:1 
   Some 40% of the U.S. adult population is at intermediate risk, but these 
individuals do not currently qualify for intensive risk factor intervention, despite 
the presence of one or more traditional risk factors. Current evidence suggests 
that the readiest tool to improve risk stratification among these individuals is the 
inflammatory biomarker hsCRP as an adjunct to global risk prediction. Strong 
evidence, as reviewed earlier, has shown that hsCRP adds prognostic 
information at all LDL-C levels of the Framingham risk score and of the 
metabolic syndrome. Thus, hsCRP evaluation, along with standard lipid 
screening and knowledge of family history, may become common practice in 
the near future. The pathophysiologic implications that follow from the 
inflammatory hypothesis of atherothrombosis should lead to novel interventions 
for primary prevention as well as for the treatment of acute ischemia. 
Direct Plaque Imaging: 1 
  In addition to the use of inflammatory markers and family history, 
strategies to detect vascular disease will likely take several forms. One approach 
eschews risk factor measurement, but identifies preclinical disease through the 
noninvasive detection of atherosclerotic plaque. Such an approach can never 
12
truly prevent disease; it can only lead to early detection. However, because 
many therapies can delay clinical expression of disease once existing lesions are 
diagnosed, this approach merits consideration. 
   Several studies indicate that coronary calcification, as detected by 
computed tomography (CT), can detect preclinical atherosclerosis. Much 
controversy remains, however, as to whether this approach is cost-effective or 
has an acceptable false-negative rate. Enrollment in some of these studies may 
be biased by referral patterns or self-selection by patients. Part of the difficulty 
with coronary calcification as a cl inical biomarker that CT imaging probably 
detects the plaques least likely to rupture and does not detect the less calcified 
lesions that appear to cause most clinical events. Thus, although coronary 
calcium provides a noninvasive measure of atherosclerotic burden, patients with 
low calcium scores cannot be dismissed as being at low risk. Furthermore, the 
clinical determinants of calcification are largely unknown and may not reflect 
propensity to plaque rupture. Studies indicating that hsCRP elevation 
corresponds to an approximate doubling of the risk of plaque rupture at all 
levels of coronary calcium have demonstrated the complexity of this approach. 
Although advocates of CT imaging have noted that sensitivity for the presence 
of angiographic coronary disease is comparable with that of noninvasive stress 
testing, such as perfusion scintigraphy or dobutamine echocardiography, the 
specificity of CT imaging in this setting is low. 
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Pathophysiology of CAD/ACS: 
        Most commonly ACS results from ongoing atherosclerotic process but 
there are other causes for myocardial infarction like CTD, metabolic disorders, 
hematological, embolism, trauma, congenital anamolies.1 
        During the natural evolution of atherosclerotic plaques, especially lipid-
laden plaques, an abrupt and catastrophic transition can occur, characterized by 
plaque disruption .25,26  Some patients have a systemic predisposition to plaque 
disruption that is independent of traditional risk factors.27 Plaque disruption 
exposes substances that promote platelet activation and aggregation, thrombin 
generation, and ultimately thrombus formation. The resultant thrombus 
interrupts blood flow and leads to an imbalance between oxygen supply and 
demand and, if this imbalance is severe and persistent, to myocardial necrosis. 
         By gross pathology MI can be divided as transmural and sub endocardial 
infarcts.24  Ultra microscopy reveals various stages of repair and injury. 24 These 
changes can be potentially reversible when treated early.1  
14
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Symptoms: 28 
1. Chest pain 
2. Diaphoresis  
3. Dyspnea 
4. Fatigue 
5. Light headedness 
6. Palpitations 
7. Acute confusion 
8. Indigestion 
9. Nausea vomiting 
In up to one-half of cases, a precipitating factor appears to be present 
before STEMI, such as vigorous physical exercise, emotional stress, or a 
medical or surgical illness. Although STEMI may commence at any time of the 
day or night, circadian variations have been reported such that clusters are seen 
in the morning within a few hours of awakening. 
Pain is the most common presenting complaint in patients with STEMI. 
The pain is deep and visceral; adjectives commonly used to describe it are 
heavy, squeezing, and crushing, although, occasionally, it is  described as 
stabbing or burning. It is similar in character to the discomfort of angina 
pectoris but commonly occurs at rest, is usually more severe, and lasts longer. 
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Typically, the pain involves the central portion of the chest and/or the 
epigastrium, and, on occasion, it radiates to the arms. Less common sites of 
radiation include the abdomen, back, lower jaw, and neck. The frequent location 
of the pain beneath the xiphoid and epigastrium and the patients' denial that they 
may be suffering a heart attack are chiefly responsible for the common mistaken 
impression of indigestion. The pain of STEMI may radiate as high as the 
occipital area but not below the umbilicus. It is often accompanied by weakness, 
sweating, nausea, vomiting, anxiety, and a sense of impending doom. The pain 
may commence when the patient is at rest, but when it begins during a period of 
exertion, it d oes not usually subside with cessation of activity, in contrast to 
angina pectoris. 
  The pain of STEMI can simulate pain from acute pericarditis pulmonary 
embolism acute aortic dissection, costochondritis, and gastrointestinal disorders. 
These conditions should therefore be considered in the differential diagnosis. 
Radiation of discomfort to the trapezius is not seen in patients with STEMI and 
may be a useful distinguishing feature that suggests pericarditis is the correct 
diagnosis. However, pain is not uniformly present in patients with STEMI. The 
proportion of painless STEMIs is greater in patients with diabetes mellitus, and 
it increases with age. In the elderly, STEMI may present as sudden-onset 
breathlessness, which may progress to pulmonary edema. Other less common 
presentations, with or without pain, include sudden loss of consciousness, a 
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confusional state, a sensation of profound weakness, the appearance of an 
arrhythmia, evidence of peripheral embolism, or merely an unexplained drop in 
arterial pressure. 
Signs:29 
1. Signs of sympathetic activation: pallor, sweating, tachycardia 
2. Signs of vagal activation: vomiting, bradycardia 
3. Signs of impaired myocardial function 
4. Hypotension, oliguria, cold peripheries 
5. Narrow pulse pressure 
6. Raised JVP 
7. Third heart sound 
8. Quiet first heart sound 
9. Diffuse apical impulse 
10. Lung crepitations  
 
Signs of tissue damage :  fever 
Signs of complications :  e.g. mitral regurgitation, pericarditis 
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Cardiac Examination:1 
Palpation:  
Palpation of the precordium may yield normal findings, but in patients 
with transmural STEMI, it m ore commonly reveals a presystolic pulsation, 
synchronous with an audible fourth heart sound, which reflects a vigorous left 
atrial contraction filling a ventricle with reduced compliance. In the presence of 
LV systolic dysfunction, an outward movement of the left ventricle can be 
palpated in early diastole, coincident with a third heart sound. 
Auscultation:  
Heart Sounds: 
The heart sounds, particularly the first sound, are frequently muffled and 
occasionally inaudible immediately after the infarct, and their intensity 
increases during convalescence. A soft first heart sound may also reflect 
prolongation of the P-R interval. Patients with marked ventricular dysfunction 
and/or left bundle branch block may have paradoxical splitting of the second 
heart sound. 
A fourth heart sound is almost universally present in patients in sinus 
rhythm with STEMI. However, it has limited diagnostic value because it is 
commonly audible in most patients with chronic ischemic heart disease and is 
recordable, although not often audible, in many normal subjects older than 45 
years of age. 
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A third heart sound in patients with STEMI usually reflects severe LV 
dysfunction with elevated ventricular filling pressure. It is caused by rapid 
deceleration of transmitral blood flow during protodiastolic filling of the left 
ventricle and is usually heard in patients with large infarctions. This sound is 
detected best at the apex, with the patient in the left lateral recumbent position. 
A third heart sound may be caused not only by LV failure but also by increased 
inflow into the left ventricle, as occurs when mitral regurgitation or ventricular 
septal defect complicates STEMI. Third and fourth heart sounds emanating 
from the left ventricle are heard best at the apex; in patients with right 
ventricular infarcts, these sounds can be heard along the left sternal border and 
increase on inspiration. 
Murmurs:  
Transient or persistent systolic murmurs are commonly audible in 
patients with STEMI and generally result from mitral regurgitation secondary to 
dysfunction of the mitral valve apparatus (e.g., papillary muscle dysfunction, 
LV dilation). A new, prominent, apical holosystolic murmur, accompanied by a 
thrill, may represent rupture of a h ead of a papillary muscle . The findings in 
cases of rupture of the interventricular septum are similar, although the murmur 
and thrill are usually most prominent along the left sternal border and may be 
audible at the right sternal border as well. The systolic murmur of tricuspid 
regurgitation (caused by right ventricular failure because of pulmonary 
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hypertension and/or right ventricular infarction or by infarction of a right 
ventricular papillary muscle) is also heard along the left sternal border. It is 
characteristically intensified by inspiration and is accompanied by a prominent 
c-v wave in the jugular venous pulse and a right ventricular fourth sound. 
Friction Rubs:  
Pericardial friction rubs may be heard in patients with STEMI, especially 
those sustaining large transmural infarctions. Rubs are notorious for their 
evanescence and hence are probably even more common than reported. 
Although friction rubs can be heard within 24 hours or as late as 2 weeks after 
the onset of infarction, most commonly they are noted on the second or third 
day. Occasionally, in patients with extensive infarction, a loud rub can be heard 
for many days. Patients with STEMI and a pericardial friction rub may have a 
pericardial effusion on echocardiographic study, but only rarely does this cause 
the classic electrocardiographic changes of pericarditis. Delayed onset of the rub 
and the associated discomfort of pericarditis (as late as 3 months postinfarction) 
are characteristic of the now rare postmyocardial infarction syndrome (Dressler 
syndrome). 
Pericardial rubs are most readily audible along the left sternal border or 
just inside the apical impulse. Loud rubs may be audible over the entire 
precordium and even over the back. Occasionally, only the systolic portion of a 
rub is heard; it can be confused with a systolic murmur, and the diagnosis of 
22
rupture of the ventricular septum or mitral regurgitation may be incorrectly 
considered 
Investigations: 
Cardiac enzymes: 
30 
            These considerations apply directly to patients on the UA/NSTEMI end 
of the ACS spectrum, a general discussion of cardiac biomarkers is presented 
here because the scientific aspects of the pathophysiologic concepts and assay 
methodology overlap when biomarkers are used to evaluate STEMI patients. It 
should be emphasized that clinicians should not wait for the results of 
biomarker assays to initiate treatment for the STEMI patient. Because there is 
time urgency for reperfusion in STEMI, the 12-lead ECG should serve to 
initiate such strategies.1 
23
                Necrosis compromises the integrity of the sarcolemmal membrane; 
intracellular macromolecules (serum cardiac markers) begin to diffuse into the 
cardiac interstitium, and ultimately into the microvasculature and lymphatics in 
the region of the infarct .The rate of appearance of these macromolecules in the 
peripheral circulation depends on several factors, including intracellular 
location, molecular weight, local blood and lymphatic flow, and rate of 
elimination from the blood.1 
Echocardiograpy: 
                 The relative portability of echocardiographic equipment makes this 
technique ideal for the assessment of patients with MI hospitalized in the 
coronary care unit or even in the emergency department before admission .86 In 
patients with chest pain compatible with MI but with a  
Non-diagnostic ECG, the finding of a distinct region of disordered contraction 
on echocardiography can be helpful diagnostically because it supports the 
diagnosis of myocardial ischemia. Echocardiography can also help evaluate 
patients with chest pain and a nondiagnostic ECG who are suspected of having 
an aortic dissection. The identification of an intimal flap consistent with an 
aortic dissection is a cr itical observation because it represents a m ajor 
contraindication to fibrinolytic therapy.1  
Other investigations include CT, Cardiac MRI, nuclear imaging. The 
estimate of the infarct size can be done by ECG, enzymes and Cardiac MRI. 
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CRP and hs-CRP: 
    CRP, named for its capacity to precipitate the somatic C-
polysaccharide of Streptococcus pneumoniae, was the first acute-phase protein 
to be described and is an exquisitely sensitive systemic marker of inflammation 
and tissue damage . The acute-phase response comprises the nonspecific 
physiological and biochemical responses of endothermic animals to most forms 
of tissue damage, infection, inflammation, and malignant neoplasia. In 
particular, the synthesis of a number of proteins is rapidly upregulated, 
principally in hepatocytes, under the control of cytokines originating at the site 
of pathology. Other acute-phase proteins include proteinase inhibitors and 
coagulation, complement, and transport proteins, but the only molecule that 
displays sensitivity, response speed, and dynamic range comparable to those of 
CRP is serum amyloid A protein (SAA). 
                 In healthy young adult volunteer blood donors, the median 
concentration of CRP is 0.8 mg/l, the 90th centile is 3.0 mg/l, and the 99th 
centile is 10 mg/l , but, following an acute-phase stimulus, values may increase 
from less than 50 μg/l to more than 500 mg/l, that is, 10,000-fold. Plasma CRP 
is produced only by hepatocytes, predominantly under transcriptional control by 
the cytokine IL-6, although other sites of local CRP synthesis and possibly 
secretion have been suggested. De novo hepatic synthesis starts very rapidly 
after a single stimulus, serum concentrations rising above 5 mg/l by about 6 
25
hours and peaking around 48 hours. The plasma half-life of CRP is about 19 
hours and is constant under all conditions of health and disease, so that the sole 
determinant of circulating CRP concentration is the synthesis rate , which thus 
directly reflects the intensity of the pathological process(es) stimulating CRP 
production. When the stimulus for increased production completely ceases, the 
circulating CRP concentration falls rapidly, at response, such as plasma 
viscosity and the erythrocyte sedimentation rate. Importantly, acute-phase CRP 
values show no diurnal variation and are unaffected by eating. Liver failure 
impairs CRP production, but no other intercurrent pathologies and very few 
drugs reduce CRP values unless they also affect the underlying pathology 
providing the acute-phase stimulus. The CRP concentration is thus a very useful 
nonspecific biochemical marker of inflammation, measurement of which 
contributes importantly to (a) screening for organic disease, (b) monitoring of 
the response to treatment of inflammation and infection, and (c) detection of 
intercurrent infection in immunocompromised individuals, and in the few 
specific diseases characterized by modest or absent acute-phase responses . It is 
not known why systemic lupus erythematosus and the other conditions listed 
with it in table fail to elicit major CRP production despite evident inflammation 
and tissue damage, nor why the CRP responses to intercurrent infection are 
apparently intact in patients with such conditions  
CRP in Disease process:31 
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1.Infection:         
1. Bacterial Systemic infection 
2. Severe fungal infections 
3. Mycobacterial infections  
4. Viral infection 
2.Allergic complications: 
1. Rheumatic fever 
3.Inflamatory  
1. Erythema nodosum 
2. Rheumatoid arthritis 
3. Juvenile chronic arthritis   
4. Ankylosing spondylitis  
5. Psoriatic arthritis,  
6. Systemic vasculitis  
7. Polymyalgia rheumatica 
8. Reiter disease  
9. Crohn disease  
10. Familial Mediterranean fever 
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4. Necrosis 
1. Myocardial infarction 
2. Tumor embolization  
3. Acute pancreatitis 
 
5. Trauma       
1. Surgery 
2. Burns  
3. Fractures 
6.Malignancy 
1. Lymphoma  
2. Carcinoma  
3. Sarcoma 
Functions of CRP: 
i. It  recognizes  and  ‘scavenges’  cellular  debris  and  promotes  its clearance. 
ii. Protects against infection with pneumococci and H. Influenza. iii.       
Complement activation by CRP exacerbates ischaemic injury. 
iv. It is proatherogenic – by binding to phospholipids and lipoproteins. 
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v. It is prothrombotic – CRP stimulates tissue factor production by 
macrophages. 
vi.  CRP suppresses polymorph migration (which is anti-inflammatory). 
 
            hs-CRP levels could be used for risk assessment and as a diagnostic and 
prognostic marker in myocardial infarction patients .32 
Treatment: 
Risk stratification:28 
1  Age 
2. Systolic blood pressure 
3. Killip classification 
4. Heart rate 
5. Location of MI 
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These five parameters account for 90% of the prognostic information for 
30 day mortality. 
Antithrombotic Agents:2 
   The use of antiplatelet and anticoagulant therapy during the initial 
phase of STEMI is based on extensive laboratory and clinical evidence that 
thrombosis plays an important role in the pathogenesis of this condition. The 
primary goal of treatment with antiplatelet and anticoagulant agents is to 
maintain patency of the infarct-related artery, in conjunction with reperfusion 
strategies. A secondary goal is to reduce the patient's tendency to thrombosis 
and, thus, the likelihood of mural thrombus formation or deep venous 
thrombosis, either of which could result in pulmonary embolization. The degree 
to which antiplatelet and anticoagulant therapy achieves these goals partly 
determines how effectively it reduces the risk of mortality from STEMI. 
Aspirin is the standard antiplatelet agent for patients with STEMI. The 
most compelling evidence for the benefits of antiplatelet therapy (mainly with 
aspirin) in STEMI is found in the comprehensive overview by the Antiplatelet 
Trialists' Collaboration. Data from nearly 20,000 patients with MI enrolled in 15 
randomized trials were pooled and revealed a relative reduction of 27% in the 
mortality rate, from 14.2% in control patients to 10.4% in patients receiving 
antiplatelet agents. 
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   Inhibitors of the P2Y12 ADP receptor prevent activation and 
aggregation of platelets. The addition of the P2Y12 inhibitor clopidogrel to 
background treatment with aspirin to STEMI patients reduces the risk of clinical 
events (death, reinfarction, stroke) and, in patients receiving fibrinolytic 
therapy, has been shown to prevent reocclusion of a s uccessfully reperfused 
infarct artery. New P2Y12 ADP receptor antagonists, such as prasugrel and 
ticagrelor, are more effective than clopidogrel in preventing ischemic 
complications in STEMI patients undergoing PCI, but are associated with an 
increased risk of bleeding. Glycoprotein IIb/IIIa receptor inhibitors appear 
useful for preventing thrombotic complications in patients with STEMI 
undergoing PCI. 
 The standard anticoagulant agent used in clinical practice is 
unfractionated heparin (UFH). The available data suggest that when UFH is 
added to a regimen of aspirin and a non-fibrin-specific thrombolytic agent such 
as streptokinase, additional mortality benefit occurs (about 5 lives saved per 
1000 patients treated). It appears that the immediate administration of 
intravenous UFH, in addition to a regimen of aspirin and relatively fibrin-
specific fibrinolytic agents (tPA, rPA, or TNK), helps to maintain patency of the 
infarct-related artery. This effect is achieved at the cost of a small increased risk 
of bleeding. The recommended dose of UFH is an initial bolus of 60 U/kg 
(maximum 4000 U) followed by an initial infusion of 12 U/kg per hour 
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(maximum 1000 U /h). The activated partial thromboplastin time during 
maintenance therapy should be 1.5–2 times the control value. 
  Alternatives to UFH for anticoagulation of patients with STEMI are the 
low-molecular-weight heparin (LMWH) preparations, a synthetic version of the 
critical pentasaccharide sequence (fondaparinux), and the direct antithrombin 
bivalirudin. Advantages of LMWHs include high bioavailability permitting 
administration subcutaneously, reliable anticoagulation without monitoring, and 
greater antiXa:IIa activity. Enoxaparin has been shown to reduce significantly 
the composite endpoints of death/nonfatal reinfarction and death/nonfatal 
reinfarction/urgent revascularization compared with UFH in STEMI patients 
who receive fibrinolysis. Treatment with enoxaparin is associated with higher 
rates of serious bleeding, but net clinical benefit—a composite endpoint that 
combines efficacy and safety—still favors enoxaparin over UFH. Interpretation 
of the data on fondaparinux is difficult because of the complex nature of the 
pivotal clinical trial evaluating it in STEMI. Fondaparinux appears superior to 
placebo in STEMI patients not receiving reperfusion therapy, but its relative 
efficacy and safety compared with UFH is less certain. Owing to the risk of 
catheter thrombosis, fondaparinux should not be used alone at the time of 
coronary angiography and PCI but should be combined with another 
anticoagulant with antithrombin activity such as UFH or bivalirudin. 
Contemporary trials of bivalirudin used an open-label design to evaluate its 
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efficacy and safety compared with UFH plus a glycoprotein IIb/IIIa inhibitor. 
Bivalirudin was associated with a l ower rate of bleeding. Patients with an 
anterior location of the infarction, severe LV dysfunction, heart failure, a history 
of embolism, two-dimensional echocardiographic evidence of mural thrombus, 
or atrial fibrillation are at increased risk of systemic or pulmonary 
thromboembolism. Such individuals should receive full therapeutic levels of 
anticoagulant therapy (LMWH or UFH) while hospitalized, followed by at least 
three months of warfarin therapy. 
Emergency CABG: 
    May be the treatment of in whom the intent is to perform direct or rescue 
percutaneous mechanical reperfusion but are found to have a critical left main 
stem lesion or severe triple vessel disease unapproachable with percutaneous 
revascularization. Right ventricular myocardial infarction is a relative 
contraindication to bypass surgery. 
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AIMS AND OBJECTIVES 
 
1. To study the level of Hs-CRP in patient with acute coronary syndrome. 
2. To study relationship between the level of Hs-CRP and disease severity 
graded by angiography. 
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MATERIAL AND METHODS 
Setting             :    This work was done at Government Rajaji Hospital,  
   affiliated to the Madurai Medical College, Madurai. 
Collaborating    
Department      :  Department of Medicine in collaboration with  
   departments of   Cardiology and biochemistry                                                       
Design of study :  Cross sectional and analytical study. 
Period of study  :   April 2011 to October 2011. 
Ethical approval :   Approval for the study was obtained from   
            the ethical committee of Government         
                  Rajaji Hospital, Madurai. 
Consent               :   Prior informed consent was obtained  
                                     from all the cases included in the study. 
 
Sample size         :   52 patients admitted with cardiology with  
                                diagnosis of acute coronary syndrome  (STEMI) 
 
Selection of study subjects: 
Cases: First ever myocardial infarction patients admitted to Govt. Rajaji 
Hospital, who satisfied the inclusion criteria were selected for the study. 
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Inclusion criteria: 
i. ECG changes suggestive of Acute Myocardial Infarction 
ii. Echocardiography – presence of regional wall motion abnormalities 
iii. Elevated enzymes – CPK  
Exclusion criteria: 
i. Chronic Kidney Disease 
ii. Extra cardiac Atherosclerosis 
iii. Acute / chronic liver diseases 
iv. Rheumatoid arthritis 
v. Documented connective tissue disorders 
vi. Previous h/o Myocardial Infarction / CAD 
vii. Fever within 1 week prior to admission 
viii. Skin infections / any other overt infections 
ix. Malignancy 
x. Children 
xi. Pregnant women  
 
 
Socio demographic data 
  Age 
  Sex 
Socio demographic and clinical data were collected. The study subjects 
were subjected to relevant investigations. 
Clinical details: 
Systolic and diastolic blood pressures were measured. 
General and Systemic examination was done. 
Cardiovascular risk factors were assessed. 
Laboratory data: 
 Blood urea estimation was done manually by using diacetyl monoxime 
(DAM) method. 
 Serum creatinine estimation was done by using COBAS auto analyser 
 Lipid profile, CPK, sugar estimation was done  
 Serum Hs CRP estimation was done by immune turbidometry method 
 ECG 12 lead Electro Cardio Gram was done 
 ECHO – Echo Cardio Graphic evaluation was done 
 ANGIO was done as a part of the work up and treatment of the patient. 
Definitions used for this study: 
Acute myocardial infarction: As defined by new consensus 
Limitations of this study: 
1. Many comorbid conditions influence on the hs CRP level 
2. Serial estimation of hs CRP was not done in this study. 
Financial support  :  Nil 
Conflicting interest :  Nil 
Statistical analysis: 
Data was prepared in Microsoft excel spread sheet. Analysis of data was 
done utilizing the software - Epidemiological Information Package 2010(Epi 
info 2010) developed by the Centers for Disease Control and Prevention-
Atlanta, USA for World Health Organization and open EPI 2.3.1. Mean 
standard deviation and ‘p’ values were calculated using this package. Chi 
Square test and ANOVA was done where ever necessary to find out 
significance of relationship between the groups. Pearson’s correlation was done 
to find the correlation of the values. 
 
 
 
 
TABLES AND INTERPRETATION 
     In the present study 52 cases of First ever myocardial infarction (AMI) 
satisfied rigid selection criteria. Their age ranged from 23 years to 67 years and 
the mean ± S.D. was 48.6 ± 10.3 years. They were divided into three groups on 
the basis of the CRP levels. 
Table 1: Age distribution between the study groups 
 
AGE (yrs) 
 
GROUP 1 
n=22 
 
GROUP 2 
n=14 
 
GROUP 3 
n=12 
 
25-35 
 
2 
 
1 
 
0 
 
36-45 
 
9 
 
2 
 
2 
 
46-55 
 
10 
 
4 
 
6 
 
56-65 
 
4 
 
5 
 
3 
 
66-75 
 
1 
 
2 
 
1 
 
Range 
 
29 – 67 
 
30 – 73 
 
40 – 67 
 
Mean 
 
48.61 
 
56.42 
 
53.41 
 
SD 
 
9.91 
 
12.02 
 
8.69 
 
P=0.07 not significant  
The patient groups did not differ statistically with reference to age. 
 
 
Chart 3: Age distribution in the study groups. 
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Chart 4: Incidence of MI according to sex. 
 
 
 
 Among the 52 cases 36 were male and 16 were female. The distribution 
within each group is as follows in the table 
Table 2: Sex distribution between the groups 
 
SEX 
 
GROUP 1  
n=22 
 
GROUP 2 
 n=14 
 
GROUP 3  
n=12 
 
MALE 
 
19 
 
7 
 
10 
 
FEMALE 
 
7 
 
7 
 
2 
 
P=0.154 not significant 
The patients groups did not differ statistically with reference to sex 
distribution. 
 
 
 
 
 
 
 
Chart 1: Sex distribution in the study group. 
 
 
 
Chart 2: Risk factor distribution in the study groups. 
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Risk Factors distribution in the study group. 
They following are the risk factor distribution in the three sub groups 
Table 3: 
 
SMOKER 
GROUP 1 
n=26 
GROUP 2 
n=14 
GROUP 3 
n=12 
P VALUE 
 
YES 
 
12    46.14% 
 
5     35.71% 
 
6        50% 
 
0.736* 
 
NO 
 
14    53.86% 
 
9     64.29% 
 
6        50% 
 
Table 4: 
 
HTN 
GROUP 1 
n=26 
GROUP 2 
n=14 
GROUP 3 
n=12 
P VALUE 
 
YES 
 
11    42.30% 
 
6     42.85% 
 
7    58.39% 
 
0.627* 
 
NO 
 
15    57.7% 
 
8     57.15% 
 
5    41.61% 
 
Table 5: 
 
T2DM 
GROUP 1 
n=26 
GROUP 2 
n=14 
GROUP 3 
n=12 
P VALUE 
 
YES 
 
6      23.07% 
 
4     28.57% 
 
4    33.33% 
 
0.792* 
 
NO 
 
20    76.93% 
 
10   71.43% 
 
8    66.67% 
 
 DYSLIPIDEMIA 
GROUP 1 
n=26 
GROUP 2 
n=14 
GROUP 3 
n=12 
P VALUE 
 
YES 
 
13     50% 
 
6    42.85% 
 
8    66.67% 
 
0.462* 
 
NO 
 
13     50% 
 
8    57.15% 
 
4    33.33% 
 
*= not significant 
The patients groups did not differ statistically with reference to the risk 
factors. 
BMI 
Table 7: 
 
BMI 
 
GROUP 1 
 n=26 
 
GROUP  2  
n=14 
 
GROUP 3  
n=12 
 
RANGE 
 
20.81 – 29.00 
 
21.67 – 29.96 
 
20.02 – 27.513 
 
MEAN 
 
25.32 
 
26.45 
 
25.49 
 
SD 
 
2.32 
 
2.43 
 
1.91 
 
p= 0.583 not statistically significant 
Thus BMI is independent of CRP levels. 
 
Chart 5: Relationship between vessel score and CRP level. 
 
 
 
Chart 6: Scatter diagram of vessel score and CRP level. 
 
 
 
 
 Table 8:  
Relationship between HS CRP level and Vessel Score 
 VESSEL SCORE 
Range Mean S.D ‘p’ value Significance 
 
Group 1 
 
0 – 2 
 
0.8 
 
0.55 
 
 
 
<0.001 
 
 
 
Significant 
 
Group 2 
 
0 – 3 
 
2 
 
0.65 
 
Group 3 
 
0 – 3 
 
2.58 
 
0.64 
 
P Value < 0.001 
The vessel score significantly correlates with the level of CRP. 
Spearman correlation coefficient is r=0.755 which is statistically 
significant. 
 
 
 
 
 
  
Chart 7: Relationship between stenosis score and CRP level. 
 
 
 
 
Chart 8: Scatter diagram of stenosis score and CRP level. 
 
  
 
Table 9:  
Relationship between HS CRP level and Stenosis Score 
 STENOSIS SCORE 
Range Mean S.D ‘p’ value Significance 
 
Group 1 
 
0 – 5 
 
3.15 
 
1.34 
 
 
 
< 0.001 
 
 
 
Significant 
 
Group 2 
 
0 – 9 
 
7.21 
 
1.81 
 
Group 3 
 
0 – 15 
 
9.83 
 
0.95 
 
P Value < 0.001 
Spearman correlation coefficient is r=0.873 which is statistically 
significant. 
The stenosis score significantly correlates with the level of  CRP. 
 
 
 
 
 Chart 9: Relationship between extent score and CRP level. 
 
 
 
Chart 10: Scatter diagram of extent score and CRP level. 
 
 
  
Table 10:  
Relationship between HS CRP level and Extent Score 
 EXTENT SCORE 
Range Mean S.D ‘p’ value Significance 
 
Group 1 
 
0 – 100 
 
62.30 
 
7.52 
 
 
 
< 0.001 
 
 
 
Significant 
 
Group 2 
 
0 – 150 
 
125.71 
 
25 
 
Group 3 
 
0 – 225 
 
190.83 
 
22.80 
 
P Value < 0.001 
Spearman correlation coefficient is r=0.953 which is statistically 
significant. 
The extent score significantly correlates with the level of CRP. 
 
 
                               
 
 
DISCUSSION 
CRP as novel risk factor in coronary artery disease: 
                 A number of large, prospective epidemiologic studies have indicated 
that hs-CRP is a s trong independent predictor of future cardiovascular events, 
including myocardial infarction, ischemic stroke, peripheral vascular disease, 
and sudden cardiac death among individuals without known CVD.40,41 
            The association between elevated hs-CRP levels and future CHD events 
has generally been consistent among these studies: subjects in the top quartile of 
hs-CRP levels have a 2 to 3 times greater relative risk of a future coronary event 
than do those in the bottom quartile.42 
           The strongest correlation between hs-CRP and risk of myocardial 
infarction occurred in those men without other risk factors – Honolulu heart 
program.43 
            The risk of cardiovascular disease burden increases with total cholesterol 
level.44 Thus hs-CRP adds to the values of the lipid profile. The AHA/CDC 
guidelines support the use of hs-CRP in primary prevention and set cutoff points 
according to relative risk categories: low risk (1.0 mg/L), average risk (1.0–3.0 
mg/L), and high risk (>3.0 mg/L).45 
 
 
CRP in Acute coronary Syndrome: 
              C-reactive protein (CRP) is the classical acute phase reactant, the 
serum level of which has long been known to increase after myocardial 
infarction.46, 47 All patients with definite myocardial infarction mounted a CRP 
response and there was a s tatistically significant correlation between the peak 
levels of CRP and of CK MB.49 There was steady increase in the CRP level 
which gradually fell down after a w eek. Persistently elevated CRP level was 
associated with increased morbidity and mortality.49 
         CRP value ≥15 mg/L identify patients with HF at entry, it also predicted 
worsening of LV function in patients without clinical signs of HF at entry. 
Conversely, low first-day CRP values in patients with acute myocardial 
infarction at entry predicted improvement of  Killip class in the subsequent 
days. Furthermore, in agreement with the results by others, peak CRP value was 
a strong independent predictor of all-cause and HF mortality during the 
following year. Although the precise role of CRP requires further elucidation, a 
focus on CRP within the first 3 days after acute myocardial infarction may 
prove useful for identification of patients who are at greater risk of heart failure 
and mortality.49 
 
 
 
CRP and angiographic severity of the lesion: 
          Several studies prove that a h igh value of CRP correlates with severity 
and complexity of the lesion. Both angiographic complexity of the culprit lesion 
and elevated troponin level are related with increased C-reactive protein levels 
in non-ST elevation acute coronary syndromes in a study by Sanchís J, et al50 
          CRP levels predict future cardiovascular events independently of CAD 
severity and correlate with number of angiographically complex coronary artery 
stenosis in patients with ACS. Thus, CRP levels are a marker of atheromatous 
plaque vulnerability and CAD activity according to R. Arroyo-Espliguero et 
al.51 
            The level of C-reactive protein (CRP) can be used to identify patients 
with the most complicated coronary lesions and the greatest degree of 
intracoronary thrombosis, but it can also help identify patients with apparently 
non-complex lesions that are susceptible to rupture - a problem that would lead 
to patient instability.52 
          There is clear trend that hs-CRP level correlates significantly with 
angiographic features of thrombi and eccentric lesions.53 
            Significantly higher hs-CRP levels are found in angiographically proven 
CAD patients with acute coronary syndrome as compared to patients with 
normal coronary angiography; and the levels of hs-CRP correlated well with the 
angiographic severity of the CAD in study by Tenzin Nyandak et al.54 
Angiographic grading of the lesions: 
         The modified Gensini score is one of the scoring systems for the grading 
of the severity of the coronary vasculature and extent of the disease. 
        Recently SYNTAX score has been used to grade the complexity of the 
lesion. This score is actually intended to plan patient for PTCA or CABG 
according to the score. A score of 1 – 22 means PTCA is favorable. A score 
greater than 33 favors CABG. Higher scores were associated with increased 
mortality and morbidity.  
         The Gensini scoring system is utilized in the evaluation of CAD severity. 
The Gensini score was calculated for each patient from the coronary arteriogram 
by assigning a severity score to each coronary stenosis according to the degree 
of luminal narrowing and its geographic importance. Reduction in the lumen 
diameter, and the roentgenographic appearance of concentric lesions and 
eccentric plaques were evaluated. 
           The stenosis score has a total score of 32 and the extent score calculated 
from the product of stenosis score and the segment score. The total extent score 
is 400. The vessel score ranges from 0 -3 according to the number of vessel 
involved. 
            In our study the mean age group was 48.6 with a deviation of this was 
similar to age group distribution as Masood et al33. In the study by Peppes et al34 
the age distribution was 60 with a deviation of 10.9 years. 
There was no significant association between the three sub groups for age 
distribution. 
         The risk factor were not significantly associated with the CRP levels as 
reported by Tenzin Nyandak et al54 and Masood et al.33 
        Danesh et al.35 reported that in general, CRP concentrations increase 
among smokers with increased cigarette consumption. Regarding the smoking 
status it was found in this current study that 46.14%, 35.71% and 50% was 
smoker in group I, group II and group III respectively. This was inferior to the 
study by hansat et al.37 
           Koenig et al36  have shown in their series 50.0 percent of the patients 
were hypertensive which is a l ittle inferior to the present study, where the  
current  study  observed  that hypertensive was 42.30% in group I, 42.85% in 
group II and 58.33% in group III. 
          In the present study, diabetes mellitus was observed in 23.07% in group I, 
28.57% in group II, 33.33% in group III. It is lower when compared to the study 
by Hansat et al.37 
The CRP levels were consistently elevated in patients with myocardial 
infarction. Peppes et al34 and H. Honarmand et al39 reported the similar findings. 
The CRP levels well correlated with the vessel score, stenosis score and the 
extent score. This was similar to the reports by Peppes et al34 , Arslan Masood et 
al38  Hansat et al37 and Tenzin Nyandak et al.54 
                       
 
CONCLUSION 
1. Sex ratio of male to female in this study is 7:3 
2. Highest incidence of myocardial infarction is in the age group of 46 – 55 years 
3. Women had higher incidence of myocardial infarction in the postmenopausal 
age 
4. CRP level is found consistently elevated in the patients developing myocardial 
infarction 
5. Significant positive correlation was observed between the extent of coronary 
artery disease and hs-CRP levels. Similarly hs-CRP levels were found to be 
higher in patients with higher degree of angiographic stenosis. This shows that 
hs-CRP levels have a positive correlation with the disease burden in CAD 
patients. 
Thus hs-CRP level may help in predicting the outcome of the patient 
admitted with acute myocardial infarction. 
 
 
 
 
  
ABBREVIATIONS 
 
ACS   –  Acute Coronary Syndrome 
STEMI  –  ST Elevation Myocardial Infarction 
NSTEMI  –  Non ST Elevation Myocardial Infarction 
CAD   –  Coronary Artery Disease 
CRP   –  C Reactive protein 
hs CRP  –  High Sensitivity C Reactive Protein 
CT   –  Computed Tomography 
LVH   –  Left Ventricular Hypertrophy 
ECHO  – Echocardiography 
ECG   –  Electrocardiogram  
MI   –  Myocardial Infarction 
Lp A   –  Lipoprotein A 
CPK   –  Creatine Phosphokinase 
HDL   –  High Density Lipoprotein 
LDL  –  Low Density Lipoprotein 
VLDL  –  Very Low Density Lipoprotein 
TGL   –  Triglycerides 
MRI   –  Magnetic Resonance Imaging 
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1 SADASIVAM 59 M 1.65 55 20.20 Y Y Y Y _ 23 26 263 1.3 338 11200 IWMI 45 2 9 180 
2 MUTHU PANDI 45 M 1.64 78 29.00 Y N Y Y _ 4.5 20 140 0.8 400 10000 AWMI 48 0 2 40 
3 CHINNAIAH 65 M 1.48 60 27.39 Y N Y N _ 21 32 90 12 434 7000 IWMI 45 3 7 160 
4 VELLAMMAL 45 F 1.68 67 23.74 N Y N Y Y 8.72 32 341 0.8 231 8900 IWMI 40 1 3 60 
5 SUNDARAM 47 M 1.59 64 25.32 N N Y N _ 7.57 19 119 1.2 350 10300 IWMI 49 2 4 80 
6 MARTEEN 42 M 1.72 70 23.66 Y Y Y N _ 12.48 19 336 0.9 200 7200 IWMI 47 1 4 80 
7 SHANMUGANATHAN 52 M 1.55 79 32.88 N Y Y N _ 8.24 28 232 0.8 577 9700 AWMI 44 1 4 80 
8 OYYANDI 60 M 1.58 58 23.23 Y N N Y _ 7.37 23 60 0.9 600 13600 IWMI 50 0 2 40 
9 MEENAL 60 F 1.66 75 27.22 N N Y Y Y 16.5 23 63 0.9 268 12500 IWMI 60 2 7 140 
10 MURUGAN 42 M 1.7 76 26.30 Y N Y Y _ 6.48 29 63 1 558 7500 AWMI 54 1 3 60 
11 MANI 54 M 1.65 69 25.34 Y Y N N _ 7.68 28 69 0.8 536 13800 AWMI 40 1 2 60 
12 JEYALAKSMI 46 F 1.55 50 20.81 N N Y N N 9.52 20 87 0.9 533 6500 IWMI 45 1 3 60 
13 PAULSAMY 55 M 1.63 63 23.71 N N N N _ 12.45 26 86 1 364 10600 AWMI 35 2 8 160 
14 KANNAN 31 M 1.68 70 24.80 Y Y N N _ 7.45 21 62 1 298 6000 AWMI 40 1 4 80 
15 CHINNAPONNU 55 F 1.54 55 23.19 N N Y Y Y 8.85 20 107 0.6 354 8400 AWMI 42 2 2 80 
16 PALANIAMMAL 39 F 1.56 52 21.37 N N N N N 4.5 18 60 0.7 144 10000 IWMI 58 1 3 60 
17 RAMA RAO 65 M 1.68 70 24.80 Y Y Y Y _ 7.96 31 109 1.1 238 9300 AWMI 32 0 2 80 
18 POOVALINGAM 37 M 1.66 75 27.22 Y N N N _ 9.57 16 139 1 191 12300 AWMI 36 1 5 85 
19 SONAI 50 M 1.7 78 26.99 Y Y Y Y _ 26 41 360 1.3 247 14200 IWMI 45 3 11 220 
20 NATARAJAN 40 M 1.61 70 27.01 Y N Y Y _ 7.5 32 128 1.2 659 12800 AWMI 40 1 3 60 
21 PITCHAI 40 M 1.59 59 23.34 N N N N _ 7.43 18 108 0.7 167 13800 AWMI 33 1 3 60 
22 MAHALINGAM 29 M 1.69 72 25.21 Y N N Y _ 6.69 17 131 0.8 99 14500 AWMI 40 0 1 20 
23 MARUDHAN 54 M 1.72 75 25.35 Y N Y N _ 13.69 24 65 0.6 93 7700 IWMI 55 2 8 130 
24 JEGATAMBAL 62 F 1.67 70 25.10 N N N Y N 11.64 22 137 0.7 548 11600 IWMI 58 3 8 130 
25 KARANAN 40 M 1.71 74 25.31 Y N Y Y _ 24 42 387 0.8 566 17000 IWMI 60 2 10 200 
26 MURUGAN 48 M 1.65 59 21.67 N N Y Y _ 22 19 150 0.8 300 19600 AWMI 33 3 10 185 
27 MUTHAMMAL 70 F 1.64 65 24.17 N N N Y Y 12.07 47 76 1.2 766 8700 IWMI 36 3 9 120 
28 PANDIARAJAN 50 M 1.56 60 24.65 N N N N _ 21 44 126 0.7 1168 7800 AWMI 42 3 8 160 
29 KRISHNAN 67 M 1.55 65 27.06 N Y Y Y _ 25 55 235 1.2 300 12300 IWMI 42 3 10 200 
30 SYEDHAMMAL 58 F 1.55 60 24.97 N Y Y N Y 13.58 19 85 1.1 197 10900 AWMI 36 1 5 100 
31 PARVATHY 53 F 1.53 55 23.50 N N N N N 26 46 280 0.9 484 7300 AWMI 40 3 15 225 
32 ALAGAN 52 M 1.66 67 24.31 N N N Y _ 25 45 125 0.8 459 15000 IWMI 52 3 11 220 
33 ALGARSAMY 55 M 1.72 74 25.01 Y N Y N _ 3.35 36 169 1.1 390 8900 AWMI 48 1 2 40 
34 MEHBOOB BEGAM 63 F 1.55 72 29.97 N N N N Y 16.56 42 106 1 590 13000 IWMI 46 2 9 150 
35 SUSEELA 65 F 1.58 65 26.04 N N N N Y 23 19 121 0.9 350 15600 AWMI 56 2 10 200 
36 VASANTHA 55 F 1.62 66 25.15 N N Y N Y 4.5 32 113 0.7 480 7500 IWMI 54 1 3 60 
37 SATHYAMOORTHY 73 M 1.65 69 25.34 Y N N Y _ 16.83 23 142 1.1 418 12400 IWMI 48 3 9 155 
38 RENGARJ 45 M 1.68 60 21.26 Y N N N _ 21 40 155 0.7 700 13000 IWMI 58 3 9 180 
39 POOCHIAMMAL 60 F 1.59 65 25.71 N N N Y Y 8.05 15 140 0.8 653 9500 AWMI 49 1 3 60 
40 MOORTHY 30 M 1.63 70 26.35 Y Y N N _ 12.54 22 89 0.8 590 6000 AWMI 52 1 4 80 
41 MUTHULAKSMI 65 F 1.69 73 25.56 N N N N Y 17.94 38 105 1.1 500 11000 IWMI 45 2 9 140 
42 THANGAVEL 60 M 1.7 73 25.26 Y N N Y _ 7.48 41 151 1.2 457 7800 IWMI 57 0 8 75 
43 SANKARAN 67 M 1.73 74 24.73 N N N Y _ 9.95 18 300 1 760 11300 AWMI 54 1 5 100 
44 THEVAR 53 M 1.66 70 25.40 N Y Y N _ 8.37 26 211 0 500 11000 AWMI 50 0 4 60 
45 RAVI 37 M 1.65 59 21.67 Y N N Y _ 10.58 29 149 0.9 190 12400 IWMI 55 2 6 105 
46 AYYANAR 40 M 1.78 79 24.93 N N N Y _ 8.58 35 98 0.6 298 11500 AWMI 50 1 3 60 
47 BABUJI 55 M 1.61 70 27.01 N N Y Y _ 13.59 22 79 0.7 495 15000 AWMI 54 2 6 120 
48 DEIVANAI 54 F 1.52 62 26.84 N Y N N Y 13.67 19 166 0.9 570 13000 AWMI 41 2 9 150 
49 ERRAMMAL 55 F 1.53 63 26.91 N N N Y Y 7.1 31 237 1.1 360 9000 AWMI 59 1 3 60 
50 KARUPPAIAH 45 M 1.65 69 25.34 Y N N N _ 6.13 34 100 1.2 300 7800 AWMI 57 0 2 40 
51 SELVA KUMAR 47 M 1.64 74 27.51 Y Y Y Y _ 21 16 63 0.6 560 17000 IWMI 48 1 8 160 
52 SELVAN 47 M 1.56 68 27.94 N N N Y _ 9.82 37 92 1.1 213 14300 IWMI 48 1 3 60 
 
